Blinatumomab for persistent myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called blinatumomab for people with refractory myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if the drug can help control muscle weakness and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years and have a confirmed diagnosis of myasthenia gravis (MG) based on symptoms and positive tests.
- Your MG is 'refractory,' meaning it has not improved enough with standard treatments or you have had serious flare-ups that required a breathing machine or other intensive care.
- You are not currently taking other biologic drugs that could affect the study, and you have not had your thymus removed in the last 6 months or have a thymoma.
- You do not have severe heart, liver, kidney, lung, or blood problems, active infections, or cancer.
- You are willing to use effective birth control if you could become pregnant, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an experimental cell therapy (UCAR T-cells) that targets two markers on immune cells to treat myasthenia gravis that hasn't improved with standard treatments. It aims to reduce symptoms and improve daily functioning.
This trial tests a drug called Blinatumomab for people with myasthenia gravis that hasn't improved with standard treatments. It aims to see if the drug can help reduce muscle weakness and daily symptoms.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.